Preliminary results of a Phase II trial show favorable outcomes for patients with recurrent epithelial ovarian cancer treated with VEGF Trap. After one month, 85% of participants showed stable disease, while 41% continued to have stable disease after fourteen weeks.
A study published in The Lancet found that women using Hormone Replacement Therapy (HRT) in the UK are 20% more likely to develop and die from ovarian cancer. Researchers analyzed data from over 948,000 postmenopausal women and found a significant increase in ovarian cancer cases and deaths among HRT users.
Researchers have discovered a biological mechanism whereby two compounds in broccoli and soy reduce the invasive and metastatic potential of breast and ovarian cancer cells. Studies also suggest that a diet high in flavonols may help reduce pancreatic cancer risk, especially in smokers.
Researchers develop genetically engineered mice with defects in Wnt/â-catenin and PI3K/Pten signaling pathways, leading to rapid tumor development and metastasis. The study aims to improve early detection and treatment of ovarian cancer.
Researchers at the University of Illinois Chicago found that knocking down a specific RNA-binding protein can inhibit ovarian tumor cell growth and invasiveness. The study suggests this protein could be a new target for diagnosis or treatment of ovarian and other cancers.
A recent study found that one-third of ovarian cancer patients in the US fail to receive recommended comprehensive surgical treatment. Factors associated with undertreatment include age, race, and insurance status. The study highlights the need for increased access to specialized care from gynecologic oncologists.
Early-stage breast cancer patients who receive a single method of treatment, such as tamoxifen or chemotherapy, have improved survival rates. Chemotherapy shows modest yet sustained benefits in relapse-free and overall survival, particularly in younger women and those without ovarian suppression.
A case-control study found that women with no annual medical visits or pelvic examinations and those with no regular health care provider are at a higher risk of ovarian cancer. Postmenopausal women are particularly vulnerable to this increased risk.
Researchers developed a new ultrasound-based test that can accurately predict ovarian response and IVF success. The antral follicle count was found to be an effective predictor of egg production, providing a less costly and invasive alternative to current hormone-based tests.
A new study reveals that expert centers with extensive experience in managing cancer are more cost-effective over time, providing significantly longer quality-adjusted survival compared to less experienced medical centers. High-volume multidisciplinary centers also show better outcomes for ovarian cancer patients.
A team of researchers has identified more than 70 markers unique to ovarian tumor blood vessels, which could lead to new screening and treatment tools. The finding suggests that these markers may be a sign of an aggressive tumor and could help inform treatment decisions.
Researchers found that ovarian cancer cells form by using the PAX8 protein to direct adult stem cell proliferation. This discovery opens new avenues for basic research and provides a potential biomarker for detecting ovarian cancer.
Women with high levels of NAC-1 protein in their ovarian cancer tissue are at increased risk of rapid and fatal recurrence. Researchers suggest testing for NAC-1 may identify patients most at risk for recurrence, guiding doctors and patients to greater vigilance and extended therapy.
A new study reveals that a specific set of symptoms and their frequency/duration can distinguish early ovarian cancer from other causes, making it a potential rapid and cost-effective screening tool. The symptom index was found to be 57% sensitive for early disease and 80% sensitive for advanced cancer.
A study found that BRCA1 and BRCA2 mutations are more common in the general population than previously reported, increasing the risk of ovarian, breast, testicular, and pancreatic cancers. The study also showed that these mutations are associated with higher risks of specific types of cancer.
UCI scientists discovered that mifepristone, a chemical compound used in abortion pills, can prevent breast tumor growth by inhibiting progesterone in breast tissue cells. This finding may lead to new prevention methods for women with a genetic predisposition to breast and ovarian cancers.
A study of over 800 twin pairs found that premature ovarian failure was three to five times greater in twins at ages 40 and 45 compared to the general population. This finding applies to both identical and non-identical twins, with a significant association observed between twin disparities in menopausal ages.
Research highlights the increased risk of suicide among breast cancer survivors for up to 30 years after diagnosis, as well as the association between hormone therapies and ovarian cancer risk. Additionally, high levels of circulating sex hormones may contribute to premenopausal breast cancer risk.
Researchers found radiofrequency ablation effective in achieving local control in selected patients with advanced ovarian cancer. The procedure resulted in complete necrosis in five of six patients, with no evidence of recurrence after treatment.
The National Institutes of Health has launched the first phase of The Cancer Genome Atlas (TCGA) project to study genomic changes in lung, brain, and ovarian cancers. The TCGA pilot project aims to identify key genomic alterations associated with cancer development and progression.
A new study from Cedars-Sinai Medical Center found that obesity can affect the progression and outcome of ovarian cancer, with obese women experiencing shorter survival times and earlier death. The study suggests that excess fat may be excreting a hormone or protein that causes ovarian cancer cells to grow more aggressively.
A new study found significant differences in histological types of epithelial ovarian cancer depending on body mass index (BMI), with obese women having a worse outcome. Higher BMI was also associated with decreasing survival rates and increased risk of mortality.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a nanoparticle delivery system that targets ovarian cancer cells, reducing tumor size and incidence by up to 98%. The fatty spheres loaded with siRNA also attack the tumor's blood supply, inducing cell suicide and increasing cell death among cancer cells.
A phase III study found that adding topotecan to standard chemotherapy for ovarian cancer does not increase overall survival or reduce cancer recurrence. The treatment instead leads to more blood-related toxicities and infections.
A preclinical study by the University of Texas M. D. Anderson Cancer Center found that chronic stress hormones stimulate tumor growth and spread in mice with ovarian cancer. Reducing stress using a medication commonly prescribed for heart disease slows tumor growth.
Researchers at Massachusetts General Hospital have identified potential ovarian cancer stem cells, which may be responsible for tumor recurrence and resistance to chemotherapy. These stem-like cells were found in mouse and human ovarian cancer lines, and were sensitive to certain treatment approaches.
A new study published in The Lancet found that a fertility technique commonly used to help couples conceive is not effective for those with a 30% chance of natural pregnancy. Intrauterine insemination with controlled ovarian hyperstimulation was no more successful than expectant management for couples with this high pregnancy rate.
A study published in JAMA found that removing ovaries can significantly reduce the risk of ovarian, fallopian tube, and peritoneal cancers in women with BRCA1 or BRCA2 gene mutations. The procedure offers an 80% reduction in cancer risk, making it a recommended preventive measure for these high-risk individuals.
A recent study found that regular paracetamol use could lower the risk of ovarian cancer by up to 30% in women. The analysis of eight major studies covering over 746,000 women revealed a strong correlation between paracetamol use and reduced ovarian cancer risk.
A study found that HtrA1 protein contributes to chemotherapy resistance in ovarian and gastric cancers by inducing cell death, while ghrelin hormone promotes the storage of energy as fat by altering gene expression in adipose cells. The findings suggest potential therapeutic targets for obesity treatment.
A study of 886 women with BRCA1 or BRCA2 genetic mutations found that prophylactic surgery reduced ovarian cancer incidence by 89% and breast cancer incidence by 47%. The results differ for BRCA1 and BRCA2 carriers, highlighting the need for tailored risk-reduction strategies.
Researchers used gene therapy to treat ovarian cancer in a mouse model, achieving complete inhibition of tumor growth in some mice and significant inhibition in others. The treatment offers a promising alternative to harsh current treatments for this deadly disease.
A study of 53 patients with ovarian cancer found that PET-CT was more accurate than CT alone and PET alone in detecting tumor recurrence. The results suggest earlier and more definitive detection of recurrent ovarian cancer through combining anatomical and functional imaging.
Researchers found that ginger causes both apoptosis and autophagic cell death in ovarian cancer cells, potentially circumventing resistance to conventional chemotherapy. The study suggests ginger may be a promising new treatment option for ovarian cancer with minimal side effects.
A pilot study found elevated Bcl-2 levels in patients with ovarian cancer, associated with 92% of cases, while CA125 tests identified only 68%. The research aims to develop a safe, non-invasive detection method for ovarian cancer.
Researchers have identified a multi-marker panel of 20 proteins that correctly recognize over 98% of serum samples from women with ovarian cancer, offering higher diagnostic power than any other published assay. The study uses novel technology to analyze multiple proteins in a single drop of blood or serum and aims to develop this scre...
A new study provides guidelines to help doctors evaluate common test abnormalities and detect ovarian cancer with precision in asymptomatic postmenopausal women. The criteria use ultrasound and CA-125 tests to identify high-risk women, resulting in accurate detection of malignancy in over 100% of cases.
Researchers found that a nitric oxide-releasing aspirin derivative, NCX-4016, reacts with thiols in ovarian cancer cells to stop proliferation and increase susceptibility to chemotherapy. This treatment may offer new hope for patients with resistant ovarian cancer.
Research found no significant association between hospital case volume and short-term mortality after ovarian cancer surgery. However, patients treated by gynecologic oncologists had the best outcomes and lowest mortality rates. Long-term outcomes were slightly more favorable for high-volume hospitals, but this difference was modest.
Women with Lynch syndrome have an equal risk of developing endometrial and colon cancers, and are at high risk for additional cancers. Prophylactic surgeries, such as hysterectomy and ovary removal, significantly reduce the risk of these two gynecological cancers.
The National Cancer Institute has issued a clinical announcement recommending a combination of chemotherapy regimens for women with advanced ovarian cancer. The treatment involves delivering chemotherapy directly into the abdominal cavity (intraperitoneal, or IP) in addition to traditional IV chemotherapy. This approach appears to be m...
A New England Journal of Medicine study found that women who received intraperitoneal chemotherapy had a median survival time 16 months longer than those receiving IV chemotherapy alone. The importance of referral to physicians with expertise in surgical management of ovarian cancer is highlighted.
A large population-based cohort of Swedish women found a significant association between tea consumption and reduced risk of ovarian cancer. Women who drank two or more cups of tea per day had a 46% lower risk compared to non-drinkers.
Researchers developed a genetic profile of ovarian cancer that predicts survival and identifies key genes involved in chemotherapy response. The study used microarray analysis to identify a gene expression profile known as the Chemotherapy Response Profile, which confirms the importance of genes such as BAX.
Researchers have found that combining the monoclonal antibody C225 with photodynamic therapy in a mouse model of ovarian cancer resulted in substantial tumor reduction and improved survival rates compared to single-agent treatments. This innovative approach may provide new hope for women diagnosed with this aggressive form of cancer.
A study by Mayo Clinic researchers found that radical surgery significantly improves five-year survival rates for patients with ovarian cancer and diaphragm disease. The procedure resulted in a 55% survival rate compared to 28% for those who did not undergo surgery.
Researchers have found a surge in Rsf-1 gene copies in 13.2% of high-grade ovarian cancers, but not in low-grade or benign tumors. The amplification is associated with poorer survival rates, and the Hopkins scientists are working to develop targeted therapies.
A study found that a thorough family history is an effective measure for cancer risk, with 20% of women with breast or ovarian cancer having a high risk of BRCA1/BRCA2 mutations. Women of Ashkenazi ancestry were more likely to have high-risk family histories than those of non-Ashkenazi ancestry.
A new protocol has been developed to identify women with high-risk family histories of breast or ovarian cancer, allowing for more accurate data collection and analysis. The study found that 20.6% of participants had elevated risk levels, with higher rates among those with Ashkenazi Jewish ancestry.
A study of 199 families with multiple cases of breast cancer found that women from these families do not have an increased risk of ovarian cancer. Despite this, the genetic mechanism for up to half of hereditary breast cancer remains unknown, prompting ongoing research at Memorial Sloan Kettering Cancer Center.
Researchers successfully transplanted whole ovary from frozen-thawed sheep into the same animal or another, showing long-term ovarian function. The technique could become a treatment for women facing premature ovarian failure and potentially revolutionize organ transplantation.
The US Task Force does not recommend routine screening for breast cancer gene mutations in women without a specific family medical history. However, they do suggest screening for women with a history of Ashkenazi Jewish descent, young-onset breast cancer, or multiple relatives with breast and ovarian cancer.
Researchers discovered a potential biomarker, PKCi, which predicts outcome in non-serous ovarian cancer when combined with Cyclin E. High levels of the protein correspond to reduced survival rates.
Researchers found that women with ovarian cancer were more likely to present to physicians with abdominal swelling or pelvic pain up to 12 months before diagnosis. Diagnostic testing showed only a minority of patients received necessary tests, highlighting the need for earlier detection.
Researchers have found that nearly 42% of ovarian cancer patient tumor tissues contain alterations in the protein km23. This discovery suggests km23 as a possible diagnostic indicator and therapeutic target for ovarian cancer. Further studies aim to develop a screening test and targeted therapies using km23.
A meta-analysis of epidemiological studies found a positive correlation between milk consumption and an increased risk of ovarian cancer. High intakes of dairy foods and lactose may contribute to this association, with a 13% increase in risk seen for every 10 grams of lactose consumed daily.
A study published in the International Journal of Cancer has found three proteins present in the blood of women with breast and ovarian cancer, but not in those without cancer. This breakthrough could lead to a simple blood test for early detection and improved patient outcomes.
A study of 360 women with borderline ovarian tumours found that conservative surgery can preserve fertility, especially for younger women with unilateral BOT. However, the recurrence rate was high at 16.6% over an average 70-month period.
Strong social attachments are associated with lower IL-6 levels, reduced mortality risk, and better quality of life among women with advanced ovarian cancer. Women with weak social connections have higher IL-6 levels, which promotes tumor growth and disease progression.
A study at the American Society of Clinical Oncology meeting found that a targeted cancer drug combined with low-dose chemotherapy shrinks ovarian cancer tumors in nearly half of patients. The treatment also slows disease progression and achieves stable disease in 59% of patients.